CMPS

NEUTRALProduct

COMPASS Pathways Plc - American

2026-09-21

Price

$15.01

-1.18%

This is the 2026-09-21 snapshot — the signals and analysis for CMPS as of this single trading day.

View full CMPS research hub →

Score8.5Priority

Signals4/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.3xvs 20d avg

Analysis

CMPS is experiencing High-Conviction Price Discovery driven by breakthrough 52-week Phase 3 data for its COMP360 psilocybin therapy and an ongoing FDA rolling review. The stock's robust technical posture, highlighted by STEADY_CLIMB and PERFECT_STACK signals, reflects aggressive institutional accumulation following upbeat management commentary at the recent Deutsche Bank Healthcare Summit. In the current RISK_ON macro regime, market participants are eager to reward high-beta biotech innovators, explaining the stock's +12.6% monthly surge and strong relative strength against the broader market.

Fired Signals

STEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKPANIC REVERSAL

Key Takeaways

Actionable Thesis: Ride the institutional momentum generated by the COMP360 Phase 3 clinical success and rolling FDA review, supported by a highly risk-receptive macro environment.
Key Risk: As a pre-revenue clinical-stage biotech, any delays in the FDA rolling review process or a sudden macro shift out of high-beta assets could trigger a sharp multiple compression.
What to Watch: Maintain a trailing stop near the $13.23 support level while monitoring the upcoming TD Cowen summit for further commercialization details.

← Back to 2026-09-21 View Full CMPS History →Yahoo Finance &nearr;